Bexion Pharmaceuticals Inc. has selected Cytovance Biologics, Inc. to manufacture the protein component and active ingredient for Bexion’s first clinical compound, BXQ-350 to support Bexion’s drug development efforts, including planned Phase II trials.    BXQ-350 is a formulation of the human lysosomal protein, Saposin C, and the phospholipid dioleoylphosphatidylserine (DOPS). The companies are working on the scale-up process in anticipation of increased drug requirements. Bexion recently c...